Sifting through countless of stocks in the Life Sciences Tools & Services industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Tempus AI, Inc., 10x Genomics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Tempus AI, Inc., 10x Genomics and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Tempus AI, Inc., 10x Genomics and Inc.

Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician’s desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3’ gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Latest Life Sciences Tools & Services and Tempus AI, Inc., 10x Genomics, Inc. Stock News

As of March 13, 2026, Tempus AI, Inc. had a $8.9 billion market capitalization, compared to the Life Sciences Tools & Services median of $1.1 million. Tempus AI, Inc.’s stock is down 15.4% in 2026, down 4.4% in the previous five trading days and up 9.85% in the past year.

Currently, Tempus AI, Inc. does not have a price-earnings ratio. Tempus AI, Inc.’s trailing 12-month revenue is $1.3 billion with a -19.3% net profit margin. Year-over-year quarterly sales growth most recently was 83.0%. Analysts expect adjusted earnings to reach $-0.416 per share for the current fiscal year. Tempus AI, Inc. does not currently pay a dividend.

As of March 13, 2026, 10x Genomics, Inc. had a $2.4 billion market cap, putting it in the 58th percentile of all stocks. 10x Genomics, Inc.’s stock is up 15.2% in 2026, down 9.7% in the previous five trading days and up 73.18% in the past year.

Currently, 10x Genomics, Inc. does not have a price-earnings ratio. 10x Genomics, Inc.’s trailing 12-month revenue is $642.8 million with a -6.8% net profit margin. Year-over-year quarterly sales growth most recently was 0.6%. Analysts expect adjusted earnings to reach $-0.137 per share for the current fiscal year. 10x Genomics, Inc. does not currently pay a dividend.

How We Compare Tempus AI, Inc., 10x Genomics and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Tempus AI, Inc., 10x Genomics and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Tempus AI, Inc., 10x Genomics and Inc. Stock Value Grades

Company	Ticker	Value
Tempus AI, Inc.	TEM	F
10x Genomics, Inc.	TXG	D

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Tempus AI, Inc. has a Value Score of 5, which is Ultra Expensive. 10x Genomics, Inc. has a Value Score of 26, which is Expensive.

The Value Stock Winner: No Clear Winner

Neither Tempus AI, Inc., 10x Genomics or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Tempus AI, Inc., 10x Genomics or Inc. is the better investment when it comes to value.

Tempus AI, Inc., 10x Genomics and Inc.’s Quality Grades

Company	Ticker	Quality
Tempus AI, Inc.	TEM	F
10x Genomics, Inc.	TXG	C

Like the Value Grade, AAII’s A+ Investor Quality Grade comes from the percentile rank of key metrics. Specifically, the Quality Score is the percentile rank of the average of the percentile ranks of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and the F-Score.

The score is variable, meaning it can consider all eight measures or, should any of the eight measures not be valid, the remaining measures that are valid. To be assigned a Quality Score, stocks must have a valid (non-null) measure and corresponding ranking for at least four of the eight quality measures.

The Quality Score is used to assess the underlying “quality” of a particular stock. A higher-quality stock possesses traits associated with upside potential and reduced downside risk. Backtesting of the Quality Grade shows that stocks with higher grades, on average, outperformed stocks with lower grades over the period of 1998 through 2019.

Stocks receive better grades (higher scores) for having higher scores for the quality subcomponents and worse grades (lower scores) for lower scores for the subcomponents.

Tempus AI, Inc. has a Quality Score of 17, which is Very Weak. 10x Genomics, Inc. has a Quality Score of 60, which is Average.

The Quality Stock Winner: No Clear Winner

Neither Tempus AI, Inc., 10x Genomics or Inc. has a high enough Quality Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Tempus AI, Inc., 10x Genomics or Inc. is the better investment when it comes to quality.

Tempus AI, Inc., 10x Genomics and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Tempus AI, Inc.	TEM	B
10x Genomics, Inc.	TXG	A

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Tempus AI, Inc. has a Earnings Estimate Score of 65, which is Positive. 10x Genomics, Inc. has a Earnings Estimate Score of 83, which is Very Positive.

The Earnings Estimate Revisions Grade Winner: 10x Genomics, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, 10x Genomics, Inc. has a better Earnings Estimate Revisions Grade than Tempus AI, Inc.. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, 10x Genomics, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Tempus AI, Inc., 10x Genomics and Inc. Grades

In addition to Value, Quality and Estimate Revisions, A+ Investor also provides grades for Growth and Momentum.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Tempus AI, Inc., 10x Genomics and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Tempus AI, Inc., 10x Genomics or Inc. Stock?

Overall, Tempus AI, Inc. stock has a Value Score of 5, Estimate Revisions Score of 65 and Quality Score of 17.

10x Genomics, Inc. stock has a Value Score of 26, Estimate Revisions Score of 83 and Quality Score of 60.

Comparing Tempus AI, Inc., 10x Genomics and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.